Hormonal
Supplementation with omega-3 polyunsaturated fatty acids (EPA and DHA) reduces systemic inflammation and improves cardiovascular risk profiles in patients with metabolic syndrome and cardiovascular disease.
For individuals with established cardiovascular disease or high risk (e.g., post-heart attack, metabolic syndrome), incorporating omega-3 fatty acids (EPA/DHA) through diet (fatty fish) or supplementation is strongly supported by evidence to reduce mortality and cardiovascular events. The mechanism involves lowering inflammatory markers (CRP, IL-6, TNF-α) and improving adipokine profiles (increasing adiponectin). However, for preventing atrial fibrillation recurrence, high-dose supplementation (4g/day) has not shown benefit in recent trials, and moderate intake may be optimal for general AF risk reduction. Consult a physician for dosing, especially if on blood thinners.
Omega-3 PUFAs have been shown to decrease the production of inflammatory mediators, having a positive effect in obesity and diabetes mellitus type-2. Moreover, they significantly decrease the appearance of cardiovascular disease risk factors.
Why this rating
The paper cites multiple large-scale randomized controlled trials (GISSI, DART, PREDIMED) and meta-analyses, indicating high-quality evidence for general cardiovascular benefits, though specific AF results are mixed.
Source
Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome
Esther Tortosa-Caparrós et al. · Critical Reviews in Food Science and Nutrition · 2016
DOI 10.1080/10408398.2015.1126549
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →